Tools, Biomarkers Needed to Identify Immune-Related Toxicities

Data from the REZILIENT2 trial show meaningful intracranial activity in patients with NSCLC harboring EGFR exon 20 insertions or other uncommon mutations.

Presenting investigators at ESMO Congress 2025 highlight findings from clinical trials assessing novel therapeutics across different disease types.

Alectinib exhibited a CNS DFS improvement, with a 63% reduction in the risk of this event, and 4-year CNS DFS rate was 90.4% vs 76.1% with chemotherapy.

Georgios Evangelou, MD, MSc, speaks to the potential utility of neoadjuvant capecitabine/temozolomide in well-differentiated atypical carcinoids.

Data from the KEYNOTE-671 trial support the use of pembrolizumab among patients with non–small cell lung cancer in the perioperative setting.

Data from the phase 3 HARMONi-6 study may support ivonescimab plus chemotherapy as a new standard of care in advanced squamous non–small cell lung cancer.